DRMA Dermata Therapeutics, Inc.

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. Its lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. The company was founded in 2014 and is headquartered in San Diego, California.

$2.29
As of 12/03/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  07/31/2015
Outstanding shares:  8,328,629
Average volume:  312,827
Market cap:   $20,238,568
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    249845108
ISIN:        US2498451085
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.53
PS ratio:   0.00
Return on equity:   -12.51%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy